First Tracks Biotherapeutics (NASDAQ:TRAX) Short Interest Up ∞ in April

First Tracks Biotherapeutics (NASDAQ:TRAX) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 4,029,808 shares, a growth of ∞ from the April 15th total of 0 shares. Based on an average trading volume of 537,279 shares, the short-interest ratio is presently 7.5 days.

First Tracks Biotherapeutics Stock Down 6.9%

TRAX stock opened at $16.90 on Friday. First Tracks Biotherapeutics has a twelve month low of $14.79 and a twelve month high of $26.80.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on TRAX shares. Barclays started coverage on First Tracks Biotherapeutics in a research note on Wednesday, April 22nd. They issued an “overweight” rating and a $40.00 price objective on the stock. JPMorgan Chase & Co. initiated coverage on First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 price objective on the stock. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a report on Monday, April 27th. HC Wainwright initiated coverage on First Tracks Biotherapeutics in a report on Tuesday, April 28th. They set a “buy” rating and a $30.00 target price for the company. Finally, Piper Sandler initiated coverage on First Tracks Biotherapeutics in a report on Monday, May 4th. They set an “overweight” rating and a $54.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, First Tracks Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $39.43.